Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IO Biotech Inc IOBT

Healthcare Biotechnology
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the... see more

Recent & Breaking News (NDAQ:IOBT)

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire 7 days ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

GlobeNewswire April 15, 2024

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

GlobeNewswire April 9, 2024

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

GlobeNewswire April 5, 2024

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 6, 2024

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

GlobeNewswire March 5, 2024

IO Biotech to Present at 44th Annual Cowen Health Care Conference

GlobeNewswire February 26, 2024

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

GlobeNewswire December 21, 2023

IO Biotech Announces 2023 Third Quarter Results

GlobeNewswire November 13, 2023

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

GlobeNewswire November 13, 2023

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

GlobeNewswire November 10, 2023

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire November 8, 2023

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire November 1, 2023

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress

GlobeNewswire October 23, 2023

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire October 3, 2023

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

GlobeNewswire September 12, 2023

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire September 6, 2023

IO Biotech Announces 2023 Second Quarter Results

GlobeNewswire August 11, 2023

IO Biotech Appoints Heidi Hunter to its Board of Directors

GlobeNewswire August 11, 2023

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

GlobeNewswire August 8, 2023